Thursday, February 22, 2018
 
 
Company News: Page (1) of 1 - 10/12/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Misonix to Exhibit at NASS 2017

(October 12, 2017)

FARMINGDALE, N.Y., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will participate in the 2017 North American Spine Society (“NASS”) 32nd Annual Meeting to be held at the Orange County Convention Center in Orlando, Florida from October 25 -28, 2017.

Stavros Vizirgianakis, chief executive officer of Misonix, will deliver an analyst presentation on Wednesday, October 25 at 3:30 pm ET at the Misonix booth - #765 – to review the company’s technology, products, and corporate developments.

About NASS

The North American Spine Society (“NASS”) is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical,? value- and evidence-based spine care for patients.

About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement


With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Corporate Contact   
Misonix Contact:          
Joseph Dwyer              
631-694-9555
[email protected]    

Investor Contact
Joe Diaz                      
Lytham Partners           
602-889-9700    
[email protected]


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry
  • Pain Management Devices Market USD 5.81 Billion Revenue At 7.2 % CAGR by 2023; Exclusively Available at MarketResearchFuture.com
  • Ocular Surgery Devices Market By Application, Technology, Product, Region and Forecast 2025 - Credence Research

    Cancer
  • argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  • 2018 Global Endometriosis Strategic Business Report - Developing Regions Exhibit Immense Growth Potential
  • Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines